ClassID:

109048

C12N15/113 - page 6 - CPC Classification

Classification description:

Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor; Recombinant DNA-technology; DNA or RNA fragments; Modified forms thereof Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Recent Application in this class:
#1501
20240309365
2024-09-19

MODULATING TRANSCRIPTIONAL CONDENSATES

#1502
20240309364
2024-09-19

METHODS FOR ENHANCING UTROPHIN PRODUCTION VIA INHIBITION OF MICRORNA

#1503
20240309350
2024-09-19

MODIFIED DOUBLE-STRANDED DONOR TEMPLATES

#1504
20240309347
2024-09-19

Fusion Proteins for CRISPR-based Transcriptional Repression

#1505
20240309319
2024-09-19

COMPOSITIONS AND METHODS FOR THE GENERATION OF NEURONS AND USES THEREOF

#1506
20240309107
2024-09-19

Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

#1507
20240308952
2024-09-19

LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS

#1508
20240307390
2024-09-19

METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY TARGETING AXL SIGNALING

#1509
20240301510
2024-09-12

ASSESSING RISK FOR COLORECTAL ADENOMA RECURRENCE BY NONINVASIVE MEANS

#1510
20240301428
2024-09-12

COMPOSITIONS AND METHODS FOR CORRECTING LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2C USING EXON SKIPPING

#1511
20240301423
2024-09-12

KLF11 siRNA For Treatment Of Diabetes And Obesity

#1512
20240301422
2024-09-12

COMPOUNDS AND METHODS FOR REDUCING TAU EXPRESSION

#1513
20240301421
2024-09-12

SMALL INTERFERING RNA TARGETING C3 AND USES THEREOF

#1514
20240301420
2024-09-12

METHOD FOR MODULATING UNPRODUCTIVE ALTERNATIVE SPLICING

#1515
20240301419
2024-09-12

UNA AMIDITES AND USES THEREOF

#1516
20240301418
2024-09-12

iRNA Compositions and Methods for Silencing Filamin A (FLNA)

#1517
20240301417
2024-09-12

METHODS AND COMPOSITIONS FOR TREATING CHRONIC LIVER DISEASE AND HEPATOCELLULAR CARCINOMA

#1518
20240301416
2024-09-12

Combination of Antisense Oligomers

#1519
20240301415
2024-09-12

COMPOUNDS FOR MODULATING UNC13A EXPRESSION

#1520
20240301414
2024-09-12

MICRORNA-134 INHIBITORS

#1521
20240301413
2024-09-12

COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT OF BONE MARROW FAILURE DISEASES ASSOCIATED WITH RIBOSOMOPATHIES

#1522
20240301412
2024-09-12

COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION

#1523
20240301411
2024-09-12

COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION

#1524
20240301410
2024-09-12

OLIGONUCLEOTIDES FOR HTT-1A MODULATION

#1525
20240301409
2024-09-12

Chemically Modified Small Activating RNA

#1526
20240301408
2024-09-12

MICRORNA 195 COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

#1527
20240301407
2024-09-12

COMPOSITION COMPRISING MIR 145 INHIBITOR AS ACTIVE INGREDIENT FOR TREATMENT OF MYOCARDIAL INFARCTION

#1528
20240301406
2024-09-12

COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

#1529
20240301400
2024-09-12

METHODS FOR CONTROLLING MERISTEM SIZE FOR CROP IMPROVEMENT

#1530
20240301014
2024-09-12

MICROPEPTIDES AND USE OF SAME FOR MODULATING GENE EXPRESSION

#1531
20240300977
2024-09-12

INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF

#1532
20240299584
2024-09-12

NON-CODING RNA PROTECTING AGAINST HEART FAILURE

#1533
20240299563
2024-09-12

CELL-PENETRATING PEPTIDE CONJUGATES AND METHODS OF THEIR USE

#1534
20240299538
2024-09-12

AGENT FOR USE IN THE TREATMENT OF GLIOMA

#1535
20240299437
2024-09-12

COMPOSITION FOR ALLEVIATING HAIR GRAYING, PROMOTING HAIR GROWTH AND/OR PREVENTING OR ALLEVIATING HAIR LOSS, COMPRISING DOUBLE-STRANDED MIRNA AS ACTIVE INGREDIENT

#1536
20240299401
2024-09-12

NOVEL REDOX-BASED THERAPEUTIC APPROACH FOR TREATMENT OF CANCER

#1537
20240299301
2024-09-12

LIPID NANOPARTICLES AND METHOD FOR PREPARING SAME

#1538
20240296903
2024-09-05

METHODS OF PLACING LOCKED NUCLEIC ACIDS IN SMALL INTERFERING RNA STRANDS

#1539
20240295543
2024-09-05

CELL-BASED ASSAY FOR QUANTIFYING THE POTENCY AND EFFICACY OF CANNABINOIDS AND/OR TERPENOIDS, AND METHODS OF USE THEREOF

#1540
20240294947
2024-09-05

RNA-guided nucleases and active fragments and variants thereof and methods of use

#1541
20240294946
2024-09-05

RAPAMYCIN RESISTANT CELLS

#1542
20240294943
2024-09-05

METHOD FOR IMPROVING GENETIC ENGINEERING OF ADOPTIVE CELL THERAPIES

#1543
20240294931
2024-09-05

Means and Methods for Improved Regeneration

#1544
20240294930
2024-09-05

Organelle genome modification using polynucleotide guided endonuclease

#1545
20240294923
2024-09-05

Selective Antisense Compounds and Uses Thereof

#1546
20240294916
2024-09-05

SMALL INTERFERING RNA TARGETING CFB AND USES THEREOF

#1547
20240294915
2024-09-05

Oligonucleotides for Modulating Apolipoprotein E4 Expression

#1548
20240294914
2024-09-05

COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTION

#1549
20240294913
2024-09-05

Methods and Compositions for Treatment of Polycystic Kidney Disease

#1550
20240294912
2024-09-05

COMPLEMENT COMPONENT C3 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#1551
20240294911
2024-09-05

INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#1552
20240294910
2024-09-05

NOVEL THERAPEUTIC AGENT FOR SEPTICEMIA, AND A METHOD FOR SCREENING FOR SAME

#1553
20240294909
2024-09-05

AGENTS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF HYPOXIA AND ISCHEMIA-RELATED DISORDERS

#1554
20240294908
2024-09-05

USE OF MIRNA-485 INHIBITORS FOR TREATING DISEASES OR DISORDERS ASSOCIATED WITH ABNORMAL NLRP3 EXPRESSION

#1555
20240294907
2024-09-05

SELECTIVE DELIVERY OF OLIGONUCLEOTIDES TO GLIAL CELLS

#1556
20240294906
2024-09-05

ATXN2 IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING ATXN2-ASSOCIATED NEURODEGENERATIVE DISEASES

#1557
20240294905
2024-09-05

ANTISENSE OLIGONUCLEOTIDES FOR INCREASING SHANK3 EXPRESSION

#1558
20240294882
2024-09-05

RNA-ONLY DERIVED ORTHOMYXOVIRUSES AND ASSOCIATED VECTORS AND USES THEREOF

#1559
20240293568
2024-09-05

Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophy

#1560
20240293563
2024-09-05

GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF

#1561
20240293555
2024-09-05

CARBOHYDRATE CONJUGATES FOR THE DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES

#1562
20240293550
2024-09-05

BRANCHED OLIGONUCLEOTIDES

#1563
20240293540
2024-09-05

COMPOSITIONS AND METHODS FOR INCREASING THE SERUM HALF-LIFE OF A THERAPEUTIC AGENT TARGETING COMPLEMENT C5

#1564
20240293473
2024-09-05

METHODS FOR DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES

#1565
20240292845
2024-09-05

CONTROL OF PLANT PESTS USING RNA MOLECULES

#1566
20240287577
2024-08-29

METHOD FOR MODIFYING TARGET SITE IN GENOME OF EUKARYOTIC CELL, AND METHOD FOR DETECTING PRESENCE OR ABSENCE OF NUCLEIC ACID SEQUENCE TO BE DETECTED AT TARGET SITE

#1567
20240287566
2024-08-29

NOVEL PROCESSES FOR THE PRODUCTION OF OLIGONUCLEOTIDES

#1568
20240287526
2024-08-29

COMPOSITIONS AND METHODS FOR DELIVERING THERAPEUTIC OLIGONUCLEOTIDES TO THE CENTRAL NERVOUS SYSTEM

#1569
20240287522
2024-08-29

COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY

#1570
20240287521
2024-08-29

Allele-specific silencing therapy for DFNA21 using antisense oligonucleotides

#1571
20240287520
2024-08-29

METHOD FOR SYNTHESIS OF LINKAGE MODIFIED OLIGOMERIC COMPOUNDS

#1572
20240287519
2024-08-29

TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS

#1573
20240287518
2024-08-29

TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS

#1574
20240287517
2024-08-29

TREATMENT OF PLIN1 RELATED DISEASES AND DISORDERS

#1575
20240287516
2024-08-29

COMPOSITIONS AND METHODS OF USE FOR MUTATED HOTAIR IN THE TREATMENT OF CANCERS

#1576
20240287515
2024-08-29

RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (SINA)

#1577
20240287514
2024-08-29

OLIGONUCLEOTIDES FOR IFN-GAMMA SIGNALING PATHWAY MODULATION

#1578
20240287513
2024-08-29

Compounds and Methods for Modulating Splicing of Pre-MRNA

#1579
20240287512
2024-08-29

LIPID CONJUGATION FOR TARGETING NEURONS OF THE CENTRAL NERVOUS SYSTEM

#1580
20240287511
2024-08-29

Antisense Oligomer

#1581
20240287510
2024-08-29

OLIGONUCLEOTIDES

#1582
20240287509
2024-08-29

NANO COMPLEX FOR TARGETED REPAIRING OF NEUROVASCULAR LESION, AND PREPARATION AND USE THEREOF

#1583
20240287503
2024-08-29

COMPOSITIONS AND METHODS FOR MULTIPLEXED QUANTITATIVE ANALYSIS OF CELL LINEAGES

#1584
20240287472
2024-08-29

PSEUDOTYPED VIRAL PARTICLES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF

#1585
20240287452
2024-08-29

ENGRAFTABLE CELL-BASED IMMUNOTHERAPY FOR LONG-TERM DELIVERY OF THERAPEUTIC PROTEINS

#1586
20240287201
2024-08-29

Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

#1587
20240285803
2024-08-29

COMPOSITIONS AND METHODS FOR CELL TYPE-SPECIFIC GENE EXPRESSION IN THE INNER EAR

#1588
20240285798
2024-08-29

TREATMENT OF PRIMARY CILIARY DYSKINESIA WITH SYNTHETIC MESSENGER RNA

#1589
20240285775
2024-08-29

COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS

#1590
20240285774
2024-08-29

COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS

#1591
20240285770
2024-08-29

PRECIPITATION SUPPRESSING AGENT

#1592
20240285685
2024-08-29

GENETICALLY MODIFIED NK CELLS AND USES THEREOF

#1593
20240285669
2024-08-29

Compounds and Methods for Modulating GFAP

#1594
20240285668
2024-08-29

FORMULATIONS FOR ORAL DELIVERY OF NUCLEIC ACIDS

#1595
20240285547
2024-08-29

NEPHROTOXICITY REDUCING AGENT

#1596
20240285200
2024-08-29

Use of micro-ribonucleic acid (miRNA) to diagnose transplant rejection and tolerance of immunosuppression therapy

#1597
20240279722
2024-08-22

METHODS FOR PRODUCTION AND QUANTIFICATION OF UNIQUE MOLECULAR IDENTIFIER-LABELED BEADS

#1598
20240279687
2024-08-22

PEPTIDE NUCLEIC ACIDS FOR SPATIOTEMPORAL CONTROL OF CRISPR-CAS BINDING

#1599
20240279683
2024-08-22

VECTOR-FREE DELIVERY OF GENE EDITING PROTEINS AND COMPOSITIONS TO CELLS AND TISSUES

#1600
20240279664
2024-08-22

Conjugated antisense compounds and their use

#1601
20240279661
2024-08-22

HIPPO AND DYSTROPHIN COMPLEX SIGNALING IN CARDIOMYOCYTE RENEWAL

#1602
20240279660
2024-08-22

Methods and Compositions for Managing Vascular Conditions Using miR-483 Mimics and HIF1alpha Pathway Inhibitors

#1603
20240279659
2024-08-22

RECRUITMENT METHODS AND COMPOUNDS, COMPOSITIONS AND SYSTEMS FOR RECRUITMENT

#1604
20240279658
2024-08-22

DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO

#1605
20240279657
2024-08-22

COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF HEMOGLOBINOPATHIES

#1606
20240279656
2024-08-22

Engineered Guide RNAs and Polynucleotides

#1607
20240279655
2024-08-22

LIGAND-BINDING NUCLEIC ACID COMPLEX

#1608
20240279654
2024-08-22

COMPOUNDS FOR REDUCING PTBP1 EXPRESSION

#1609
20240279653
2024-08-22

FOLLICULIN iRNA COMPOSITIONS AND METHODS THEREOF

#1610
20240279652
2024-08-22

RNAi AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES

#1611
20240279640
2024-08-22

METHODS FOR CONTROLLING MERISTEM SIZE FOR CROP IMPROVEMENT

#1612
20240279628
2024-08-22

CRISPR/CAS9-BASED REPRESSORS FOR SILENCING GENE TARGETS IN VIVO AND METHODS OF USE

#1613
20240279610
2024-08-22

METHOD FOR IMMORTALISING VESICLE-SECRETING CELLS

#1614
20240277858
2024-08-22

CD71 BINDING FIBRONECTIN TYPE III DOMAINS

#1615
20240277851
2024-08-22

siRNA DELIVERY VECTOR

#1616
20240271148
2024-08-15

PLANT REGULATORY ELEMENTS AND USES THEREOF

#1617
20240271140
2024-08-15

LPA INHIBITOR AND USE THEREOF

#1618
20240271139
2024-08-15

Engineered Guide RNAs and Polynucleotides

#1619
20240271138
2024-08-15

METHODS AND COMPOSITIONS FOR MODULATING STING SIGNALING AND INNATE IMMUNE RESPONSES

#1620
20240271137
2024-08-15

Asymmetric Short Duplex DNA as a Novel Gene Silencing Technology and Use Thereof

#1621
20240271136
2024-08-15

COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#1622
20240271135
2024-08-15

COMPOSITION COMPRISING AN RNA THERAPEUTIC TARGETING FAT10 AND USES OF SAME FOR TREATING DISORDERS CHARACTERIZED BY ABNORMAL LIPID ACCUMULATION

#1623
20240271134
2024-08-15

OLIGONUCLEOTIDES AND COMPOSITIONS THEREOF FOR NEUROMUSCULAR DISORDERS

#1624
20240271133
2024-08-15

KRAB-Containing Zinc Finger Protein And Cancer

#1625
20240271132
2024-08-15

MIRNA INHIBITORS FOR PREVENTING AND TREATING ANEURYSMS, HYPERTENSION, ARDS AND OTHER DISEASES ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION

#1626
20240271131
2024-08-15

Chemically modified single-stranded rna-editing oligonucleotides

#1627
20240271130
2024-08-15

LIPOPHILIC SIRNA CONJUGATES FOR THE TREATMENT OF INFLAMMATORY DISEASES

#1628
20240271109
2024-08-15

ENGINEERED PROTEINS AND METHODS OF USE THEREOF

#1629
20240271097
2024-08-15

METHODS AND COMPOSITIONS FOR CELL REPROGRAMMING

#1630
20240269326
2024-08-15

METHODS AND COMPOSITIONS FOR TREATING OCULAR DISEASES AND DISORDERS

#1631
20240269189
2024-08-15

EXTRACELLULAR VESICLE-ENRICHED SECRETOME COMPOSITION DERIVED FROM INDUCED PLURIPOTENT STEM CELL DERIVED-MICROGLIA AND METHODS OF USE THEREOF

#1632
20240269161
2024-08-15

METHODS AND COMPOSITIONS FOR TAU REDUCTION GENE THERAPY

#1633
20240269160
2024-08-15

Use Of Citicoline In Regulating Respiratory Chain Function Related Protein Level And Preparing Drug For Preventing And Treating Respiratory Chain Dysfunction

#1634
20240263245
2024-08-08

COLORECTAL CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD

#1635
20240263238
2024-08-08

TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER

#1636
20240263206
2024-08-08

COMPOSITIONS AND METHODS FOR PRODUCING CIRCULAR POLYRIBONUCLEOTIDES

#1637
20240263194
2024-08-08

ANIMAL PREPARATION METHOD

#1638
20240263184
2024-08-08

METHODS OF ALTERING GENE EXPRESSION BY PERTURBING TRANSCRIPTION FACTOR MULTIMERS THAT STRUCTURE REGULATORY LOOPS

#1639
20240263179
2024-08-08

METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY

#1640
20240263178
2024-08-08

Use Of LncRNA DCRT As Drug And Its Drug For Treating Cardiovascular Diseases, Screening Method, And Preparation Method Thereof

#1641
20240263177
2024-08-08

Methods and Compositions for Adar-Mediated Editing

#1642
20240263176
2024-08-08

NUCLEIC ACID MOLECULE TARGETING MUTATION SITE OF CYP4V2 GENE AND USE THEREOF

#1643
20240263175
2024-08-08

COMPOSITION FOR TREATING METASTATIC SOLID CANCER, COMPRISING TSG6 INHIBITOR

#1644
20240263174
2024-08-08

EXPRESSION-INDUCING AGENT FOR CLASS I GLUCOSE TRANSPORTER (GLUT), AND MEDICINAL COMPOSITION AND FOOD COMPOSITION USING SAME

#1645
20240263157
2024-08-08

USE OF A FUSION PROTEIN FOR INDUCING GENETIC MODIFICATIONS BY TARGETED MEIOTIC RECOMBINATION

#1646
20240262909
2024-08-08

TIM-3 MODULATES ANTI-TUMOR IMMUNITY BY REGULATING INFLAMMASOME ACTIVATION

#1647
20240261223
2024-08-08

MODULAR LIPID COMPOUNDS AND TWO- TO THREE-COMPONENT LIPID NANOPARTICLE COMPOSITIONS

#1648
20240255880
2024-08-01

SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT

#1649
20240254659
2024-08-01

SYSTEMS AND METHODS FOR REGULATING TARGET GENES

#1650
20240254540
2024-08-01

Methods and Compositions for Determining pH

#1651
20240254509
2024-08-01

PRODUCTS AND METHODS FOR TREATMENT OF DYSTROPHIN-BASED MYOPATHIES USING CRISPR-CAS9 TO CORRECT DMD EXON DUPLICATIONS

#1652
20240254491
2024-08-01

BETA-CATENIN (CTNNB1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#1653
20240254490
2024-08-01

Short Duplex DNA as a Novel Gene Silencing Technology and Use Thereof

#1654
20240254489
2024-08-01

COMPOSITIONS AND METHODS OF TARGETING THE PAX6 SIGNALING PATHWAY TO REDUCE FORMATION OF AMYLOID BETA PLAQUES AND NEUROFIBRILLARY TANGLES

#1655
20240254488
2024-08-01

ANTISENSE OLIGOMERS FOR TREATMENT OF NON-SENSE MEDIATED RNA DECAY BASED CONDITIONS AND DISEASES

#1656
20240254487
2024-08-01

MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF

#1657
20240254486
2024-08-01

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE

#1658
20240254485
2024-08-01

SIRNAS TARGETING SLC10A1 TRANSCRIPTS, COMPOSITIONS AND USES THEREOF

#1659
20240254484
2024-08-01

SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION FACTOR 6 (STAT6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#1660
20240254483
2024-08-01

COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF FRATAXIN (FXN)

#1661
20240254482
2024-08-01

METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)

#1662
20240254481
2024-08-01

EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6

#1663
20240254480
2024-08-01

MODIFIED NUCLEIC ACID INHIBITING MICRO RNA, AND USE THEREOF

#1664
20240254462
2024-08-01

COMPOSITIONS AND METHODS FOR MODULATING SECRETED FRIZZLED RECEPTOR PROTEIN 1 (SFRP1) GENE EXPRESSION

#1665
20240254458
2024-08-01

SINGLE-COMPONENT NEAR-INFRARED OPTOGENETIC SYSTEMS FOR GENE TRANSCRIPTION REGULATION

#1666
20240254179
2024-08-01

Targeting Nuclear Speckles and DNA Speckle Association

#1667
20240254174
2024-08-01

RABIES VIRAL GLYCOPROTEIN COMPOSITIONS AND METHODS OF USE

#1668
20240252687
2024-08-01

GENE THERAPY FOR WET AGE-RELATED MACULAR DEGENERATION USING IPSC-DERIVED CELLS AS VECTORS

#1669
20240252653
2024-08-01

CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION

#1670
20240252618
2024-08-01

Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids

#1671
20240252443
2024-08-01

Nanomaterials comprising triols

#1672
20240247274
2024-07-25

FATTY ACID CONJUGATES OF NUCLEIC ACIDS

#1673
20240247271
2024-07-25

RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)

#1674
20240247265
2024-07-25

CONSTRUCTS AND METHODS FOR PREPARING CIRCULAR RNA

#1675
20240247264
2024-07-25

NOVEL lncRNA CONTROLLING CARDIAC FIBROSIS

#1676
20240247263
2024-07-25

METHOD FOR DESIGNING OLIGONUCLEOTIDE HAVING REDUCED CENTRAL TOXICITY

#1677
20240247262
2024-07-25

CRISPR/CAS SYSTEM AND METHOD FOR GENOME EDITING AND MODULATING TRANSCRIPTION

#1678
20240247261
2024-07-25

miRNA Switches for RNA-Triggered Control of RNA Interference

#1679
20240247260
2024-07-25

CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE

#1680
20240247259
2024-07-25

COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION

#1681
20240247258
2024-07-25

OLIGONUCLEOTIDE AND TARGET RNA SITE-SPECIFIC EDITING METHOD

#1682
20240247025
2024-07-25

POLYNUCLEOTIDE CONSTRUCTS

#1683
20240246898
2024-07-25

CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF

#1684
20240245784
2024-07-25

TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS

#1685
20240245782
2024-07-25

IONIZABLE LIPID COMPOUNDS

#1686
20240245620
2024-07-25

COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS

#1687
20240240202
2024-07-18

COMPOSITIONS AND THERAPEUTIC METHODS OF MICRORNA GENE DELIVERY

#1688
20240240184
2024-07-18

MICRORNAS FOR CARDIAC REGENERATION THROUGH INDUCTION OF CARDIAC MYOCYTE PROLIFERATION

#1689
20240240183
2024-07-18

Heteronucleic acid containing scpBNA or AmNA

#1690
20240240182
2024-07-18

HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF

#1691
20240240181
2024-07-18

NEUROPROTECTIVE MOLECULES AND METHODS OF TREATING NEUROLOGICAL DISORDERS AND INDUCING STRESS GRANULES

#1692
20240240180
2024-07-18

RAAV-BASED COMPOSITIONS AND METHODS

#1693
20240240179
2024-07-18

THERAPY FOR TREATMENT OF PRADER-WILLI SYNDROME

#1694
20240240178
2024-07-18

SIRNA CONSTRUCTS FOR INHIBITING GENE EXPRESSION IN TARGETED CANCER CELLS

#1695
20240240177
2024-07-18

MULTITARGETING RNA COMPOSITIONS

#1696
20240240176
2024-07-18

PREVENTION OR TREATMENT OF MYOPATHY USING MIR-33B INHIBITOR

#1697
20240240170
2024-07-18

POLYANIONIC ACIDS TO IMPROVE RECOVERY AND MINIMIZE SYSTEM LOSS

#1698
20240238435
2024-07-18

Muscle targeting complexes and uses thereof for treating myotonic dystrophy

#1699
20240238326
2024-07-18

COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING IN A SUBJECT

#1700
20240238321
2024-07-18

MODIFIED OLIGOMERIC COMPOUNDS COMPRISING TRICYCLO-DNA NUCLEOSIDES AND USES THEREOF

#1701
20240238241
2024-07-18

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PANCREATIC CANCER AND BILE DUCT CANCER

#1702
20240238027
2024-07-18

IN-SITU CRYO-IMMUNE ENGINEERING FOR CANCER IMMUNOTHERAPY

#1703
20240230644
2024-07-11

METHODS OF TREATING TRANSTHYRETIN (TTR) MEDIATED AMYLOIDOSIS

#1704
20240229129
2024-07-11

METHODS FOR ANALYZING NUCLEIC ACID SEQUENCES

#1705
20240229067
2024-07-11

COMPOSITIONS AND METHODS FOR RECOMBINANT PARVOVIRUS PRODUCTION

#1706
20240229033
2024-07-11

Compositions for Inhibiting Growth of Targeted Cells

#1707
20240229032
2024-07-11

Multitargeting RNA Immunotherapy Compositions

#1708
20240229031
2024-07-11

MICRORNA COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF NERVOUS SYSTEM DYSFUNCTION

#1709
20240229030
2024-07-11

NUCLEIC ACID MOLECULES FOR PSEUDOURIDYLATION

#1710
20240229029
2024-07-11

COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA

#1711
20240229028
2024-07-11

SPLICE-SWITCHING OLIGONUCLEOTIDES AND METHODS OF USE

#1712
20240229027
2024-07-11

NUCLEIC ACID DELIVERY SYSTEM AND APPLICATION THEREOF

#1713
20240229026
2024-07-11

CHIRAL CONTROL

#1714
20240229025
2024-07-11

siRNA AND USE THEREOF

#1715
20240229015
2024-07-11

tRNA, AMINOACYL tRNA, REAGENT FOR POLYPEPTIDE SYNTHESIS, INTRODUCTION METHOD OF UNNATURAL AMINO ACID, PRODUCTION METHOD OF POLYPEPTIDE, PRODUCTION METHOD OF NUCLEIC ACID DISPLAY LIBRARY, NUCLEIC ACID-POLYPEPTIDE CONJUGATE, AND SCREENING METHOD

#1716
20240229011
2024-07-11

MODIFIED NUCLEIC ACIDS, HYBRID GUIDE RNAS, AND USES THEREOF

#1717
20240229010
2024-07-11

TUNING CRISPR/CAS9 ACTIVITY WITH CHEMICALLY MODIFIED NUCLEOTIDE SUBSTITUTIONS

#1718
20240228945
2024-07-11

Compositions and methods for improved malonyl-CoA biosynthesis using 2-stage dynamic metabolic control

#1719
20240228660
2024-07-11

VON WILLEBRAND FACTOR (VWF) INHIBITORS

#1720
20240228546
2024-07-11

METHODS AND PRODUCTS FOR GENETIC ENGINEERING

#1721
20240226339
2024-07-11

Materials and Methods for Treatment of Hemoglobinopathies

#1722
20240226287
2024-07-11

NOVEL LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION COMPRISING THE SAME

#1723
20240226203
2024-07-11

COMPOSITIONS AND METHODS OF TREATING HUNTINGTON'S DISEASE

#1724
20240226161
2024-07-11

MIR200C-EPCAM AXIS REPROGRAMED IMMUNE CELLS FOR ENHANCED ANTI-TUMOR FUNCTION

#1725
20240226134
2024-07-11

USE OF MICRORNAS IN THE TREATMENT OF FIBROSIS

#1726
20240226111
2024-07-11

COMPOSITION FOR TREATING OSTEOARTHRITIS

#1727
20240218387
2024-07-04

CHLORELLA-BASED PRODUCTION OF EXTRACELLULAR VESICLE-EMBEDDED SMALL RNAs FOR PROPHYLACTIC OR THERAPEUTIC APPLICATIONS

#1728
20240218366
2024-07-04

COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#1729
20240218365
2024-07-04

FORMULATION OF AN ANTISENSE OLIGOMER CONJUGATE

#1730
20240218364
2024-07-04

Signal boost cascade assay

#1731
20240218363
2024-07-04

OPTIMIZED 2'- MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE

#1732
20240218362
2024-07-04

REPROGRAMMING OF NON-NEURONAL CELLS INTO NEURONS AND METHODS AND COMPOSITIONS TO TREAT NEURODEGENERATIVE DISEASES AND DISORDERS

#1733
20240218361
2024-07-04

MODULATING APOLIPOPROTEIN (A) EXPRESSION

#1734
20240218360
2024-07-04

SMALL ACTIVATING RNA INCREASING SHANK EXPRESSION AND METHOD OF TREATING INTELLECTUAL DISABILITIES AND ASSOCIATED COMORBIDITIES ASSOCIATED WITH SHANK HAPLOINSUFFICIENCY

#1735
20240218359
2024-07-04

METHOD OF TREATING BREAST CANCER IN A SUBJECT BY INHIBITING NIP7 AND A PHARMACEUTICAL COMPOSITION COMPRISING A NIP7 INHIBITOR

#1736
20240216531
2024-07-04

CHITOSAN-CONTAINING NANOPARTICLES FOR DELIVERY OF POLYNUCLEOTIDES

#1737
20240216529
2024-07-04

EXTRACELLULAR VESICLES WITH TARGETING MOIETY

#1738
20240216522
2024-07-04

MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FRIEDREICH'S ATAXIA

#1739
20240216515
2024-07-04

COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS

#1740
20240216388
2024-07-04

INHIBITOR OF SUV39H1 HISTONE METHYLTRANSFERASE FOR USE IN CANCER COMBINATION THERAPY

#1741
20240209379
2024-06-27

COMPOSITIONS AND METHODS FOR ENHANCING GENE EXPRESSION

#1742
20240209369
2024-06-27

Complement component C3 iRNA compositions and methods of use thereof

#1743
20240209368
2024-06-27

EXTRACELLULAR VESICLE COMPOSITIONS

#1744
20240209367
2024-06-27

INHIBITORY NUCLEIC ACIDS FOR FACTOR H FAMILY PROTEINS

#1745
20240209366
2024-06-27

HIGH EFFICIENCY TRANS-SPLICING FOR REPLACEMENT OF TARGETED RNA SEQUENCES IN HUMAN CELLS

#1746
20240209365
2024-06-27

METHOD FOR IMPROVING DIABETIC WOUND HEALING USING MIR-200B

#1747
20240209364
2024-06-27

COMPOUNDS AND METHODS FOR MODULATING PLP1

#1748
20240209363
2024-06-27

OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES

#1749
20240209362
2024-06-27

Linear DNA with Enhanced Resistance Against Exonucleases

#1750
20240209361
2024-06-27

TREATING CANCER

#1751
20240209360
2024-06-27

PRODUCTS AND METHODS FOR INDUCING EXON 2 SKIPPING OF THE DMD GENE IN TREATING MUSCULAR DYSTROPHY

#1752
20240209359
2024-06-27

METHODS, SYSTEMS, AND APPARATUS FOR IDENTIFYING TARGET SEQUENCES FOR CAS ENZYMES OR CRISPR-CAS SYSTEMS FOR TARGET SEQUENCES AND CONVEYING RESULTS THEREOF

#1753
20240209358
2024-06-27

COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#1754
20240209357
2024-06-27

DNA CONSTRUCTS COMPRISING ALTERNATIVE PROMOTERS

#1755
20240209339
2024-06-27

REDIRECTING RISC FOR RNA EDITING

#1756
20240209329
2024-06-27

PROGRAMMABLE CAS9-RECOMBINASE FUSION PROTEINS AND USES THEREOF

#1757
20240209317
2024-06-27

UMBILICAL CORD MESENCHYMAL CELL EXTRACELLULAR VESICLES FOR THE TREATMENT OF OSTEOARTICULAR AND AUTOIMMUNE DISEASES

#1758
20240209119
2024-06-27

MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES

#1759
20240209042
2024-06-27

COMPOSITIONS AND METHODS FOR DELIVERY AND EXPRESSION OF SMALL INHIBITORY PEPTIDES AND USE THEREOF

#1760
20240207439
2024-06-27

HIGH STEROL-CONTAINING LIPID NANOPARTICLES

#1761
20240207409
2024-06-27

ORAL DELIVERY OF OLIGONUCLEOTIDES

#1762
20240201168
2024-06-20

COMPOSITION FOR DIAGNOSIS OR TREATMENT OF ANTICANCER DRUG RESISTANCE

#1763
20240200102
2024-06-20

FUSION PROTEINS COMPRISING AN INTEIN POLYPEPTIDE AND METHODS OF USE THEREOF

#1764
20240200081
2024-06-20

NUCLEIC ACID MOLECULE CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE

#1765
20240200074
2024-06-20

METHOD AND COMPOSITIONS FOR PREVENTING TUMOR DEVELOPMENT AND METASTASIS

#1766
20240200073
2024-06-20

FUNCTIONAL NUCLEIC ACID MOLECULES DIRECTED TO TARGETS FOR NERVOUS SYSTEM DISORDERS

#1767
20240200072
2024-06-20

Allogeneic Cartilage Regeneration

#1768
20240200071
2024-06-20

NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF A TARGET GENE COMPRISING PHOSPHORODITHIOATE LINKAGES

#1769
20240200070
2024-06-20

EXPANDING THE CHEMICAL SUBSTRATES FOR GENETIC CODE REPROGRAMMING

#1770
20240200069
2024-06-20

Synthetic Near-Threshold Translational Repressors

#1771
20240200068
2024-06-20

RNAi-NANOPARTICLE CONJUGATE, COMPOSITION, AND METHOD OF SYNTHESIS THEREOF

#1772
20240200067
2024-06-20

Compositions for Modulating C9ORF72 Expression

#1773
20240200066
2024-06-20

PRODUCTS AND METHODS FOR TREATING MUSCULAR DYSTROPHY

#1774
20240200065
2024-06-20

COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT OF H-ABC LEUKODYSTROPHY

#1775
20240200064
2024-06-20

GENE THERAPY FOR INFLAMMATORY CONDITIONS

#1776
20240200063
2024-06-20

MICROGLIAL GENE SILENCING USING DOUBLE-STRANDED SIRNA

#1777
20240200062
2024-06-20

METHODS OF TREATING DUCHENNE MUSCULAR DYSTROPHY USING PEPTIDE-OLIGONUCLEOTIDE CONJUGATES

#1778
20240200061
2024-06-20

TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES

#1779
20240200060
2024-06-20

NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE

#1780
20240197830
2024-06-20

SMALL PEPTIDE COMPOSITIONS AND USES THEREOF

#1781
20240197643
2024-06-20

ORAL DELIVERY OF NANOPARTICLES FOR KIDNEY DISEASE

#1782
20240197640
2024-06-20

SYSTEMS AND METHODS FOR EXOSOME DELIVERY OF MICRORNAS FOR CELLULAR REPROGRAMMING

#1783
20240197636
2024-06-20

TISSUE-SPECIFIC NUCLEIC ACID DELIVERY BY MIXED CATIONIC LIPID PARTICLES

#1784
20240191254
2024-06-13

TRANSGENE CASSETTES DESIGNED TO EXPRESS A HUMAN MECP2 GENE

#1785
20240191240
2024-06-13

DEFINED MULTI-CONJUGATES OLIGONUCLEOTIDES

#1786
20240191239
2024-06-13

REGULATION OF GENE EXPRESSION THROUGH APTAMER-MODULATED POLYADENYLATION

#1787
20240191235
2024-06-13

TREATMENT OF TUMORS WITH MIRNA TARGETING CDK4/CDK6

#1788
20240191234
2024-06-13

Tuning cascade assay kinetics via molecular design

#1789
20240191233
2024-06-13

COMPOUNDS AND METHODS FOR REDUCING NLRP3 EXPRESSION

#1790
20240191232
2024-06-13

COMPOUNDS AND METHODS FOR REDUCING PLN EXPRESSION

#1791
20240191231
2024-06-13

SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES

#1792
20240191230
2024-06-13

CONJUGATES OF SIRNA AND ANTISENSE OLIGONUCLEOTIDES (SIRNASO) AND METHODS OF USE IN GENE SILENCING

#1793
20240191229
2024-06-13

RNA SILENCING AGENTS AND METHODS OF USE

#1794
20240191228
2024-06-13

ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF NEUROLOGICAL DISORDERS

#1795
20240191226
2024-06-13

SMAD2 INHIBITION IN BETA CELLS FOR TYPE 2 DIABETES THERAPY

#1796
20240191223
2024-06-13

TYPE VI CRISPR ORTHOLOGS AND SYSTEMS

#1797
20240189612
2024-06-13

METHODS FOR TREATING GLIOBLASTOMA OR RECURRENT GLIOBLASTOMA UTILIZING A WIRELESS SIGNAL ALONE OR IN COMBINATION WITH ONE OR MORE CANCER DRUGS, AND ASSOCIATED SYSTEMS, APPARATUSES, AND DEVICES

#1798
20240189391
2024-06-13

COMPOSITIONS AND METHODS FOR TREATING SPINAL MUSCULAR ATROPHY

#1799
20240189347
2024-06-13

USE OF MICRORNA-146A AND NANOCERIA CONJUGATE TO IMPROVE WOUND HEALING AND PROMOTE TISSUE REGENERATION

#1800
20240189339
2024-06-13

MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic Purposes